Biotech company Calithera plans its own death. Will others follow?


The Peninsula company's plan to close by the end of the first quarter is atypical in a biotech industry where executives try to keep their companies alive to the next milestone in order to raise more money.

Previous Podcast: Novo's Michael Rangel on moving his business to Miami and the fintech sector's explosive growth
Next Exact Sciences moves up time to profitability to most recent quarter